
SNYR Stock Forecast & Price Target
SNYR Analyst Ratings
Bulls say
Synergy CHC is expected to continue growing its flagship brain health supplement, FOCUSfactor, with over 34 SKUs and expanded distribution to major retailers. The global market for brain health supplements presents substantial opportunities for the company to gain market share. Despite weaker Q4 results, Synergy has a strong financial track record and several upcoming catalysts that could improve visibility and drive the stock price higher, making it undervalued.
Bears say
Synergy CHC is facing several headwinds including cash constraints and debt, weaker Q1 results due to out-of-stock products, and a highly competitive industry. However, the company has shown growth potential through its expanding product line, particularly in the large brain health supplements and energy RTD markets, and has consistently reported profits in recent quarters. With expected progress in sales, profitability, and international expansion, the stock is undervalued despite the current challenges and presents high rewards for the risks.
This aggregate rating is based on analysts' research of Synergy CHC Corp and is not a guaranteed prediction by Public.com or investment advice.
SNYR Analyst Forecast & Price Prediction
Start investing in SNYR
Order type
Buy in
Order amount
Est. shares
0 shares